Please assess the completion status of the following clinical trial:

Trial Title: Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have successfully completed either T-GD04-082 (NCT00251745) or T-GD04-083 (NCT00251758) or have a diagnosis of gastroesophageal reflux disease with or without erosive esophagitis.~Exclusion Criteria:~* Any condition that may require inpatient surgery during the course of the study.~* Use of prescription or non-prescription proton pump inhibitors, histamine (H2) receptor antagonists, sucralfate, misoprostol or prokinetics throughout the study.~* Use of antacids \[except for study supplied Gelusil®\].~* Subjects using drugs with significant anticholinergic effects such as tricyclics who cannot stay on a stable dose for 4 weeks prior to dosing and throughout the study.~* Evidence of uncontrolled systemic disease.~* Allergy to any proton pump inhibitor including Prilosec, Nexium, Prevacid, or others, any component of dexlansoprazole MR, or Gelusil/antacid.~* Need to take blood thinners.~* Need to take more than 12 doses of non-steroidal anti-inflammatory drugs per month.~* Had cancer (except basal cell cancer of the skin) within 3 years prior to screening.~* Has other esophageal disease including Barrett's esophagus or strictures requiring dilation.~* Has had radiation or cryotherapy to the esophagus.~* Has active gastric or duodenal ulcers within 4 weeks of starting study drug.~* Has a history of hypersecretory conditions such as Zollinger Ellison Syndrome.~* History of alcohol abuse.~* Has acquired immunodeficiency syndrome.~* Has had acute upper gastrointestinal bleeding within 4 weeks of endoscopy.~* Received a blood product transfusion within 3 months of taking the first dose of study drug.~* Has previously participated in another dexlansoprazole MR long-term treatment clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dexlansoprazole MR 60 mg QD (Type: EXPERIMENTAL): None
- Dexlansoprazole MR 90 mg QD (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).